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In-Stent Restenosis in the Drug-Eluting Stent Era
George D. Dangas, MD,*† Bimmer E. Claessen, MD,† Adriano Caixeta, MD,† Elias A. Sanidas, MD,†
Gary S. Mintz, MD,† Roxana Mehran, MD*†
New York, New York
The introduction of the drug-eluting stent (DES) proved to be an important step forward in reducing rates of re-
stenosis and target lesion revascularization after percutaneous coronary intervention. However, the rapid imple-
mentation of DES in standard practice and expansion of the indications for percutaneous coronary intervention
to high-risk patients and complex lesions also introduced a new problem: DES in-stent restenosis (ISR), which
occurs in 3% to 20% of patients, depending on patient and lesion characteristics and DES type. The clinical pre-
sentation of DES ISR is usually recurrent angina, but some patients present with acute coronary syndrome.
Mechanisms of DES ISR can be biological, mechanical, and technical, and its pattern is predominantly focal.
Intravascular imaging can assist in defining the mechanism and selecting treatment modalities. Based upon the
current available evidence, an algorithm for the treatment approaches to DES restenosis is proposed.
(J Am Coll Cardiol 2010;56:1897–907) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.028r
C
l
(
f
c
b
g
m
a
C
f
T
t
l
s
a
o
f
u
f
t
f
(
a
a
I
T
B
cestenosis after angioplasty and stent implantation has been
istorically considered the most significant problem in coro-
ary interventional treatment (1). Drug-eluting stents (DES)
ave dramatically reduced the rates of restenosis and target
esion revascularization (TLR) compared with bare-metal
tents (BMS) (2). However, a low rate of in-stent restenosis
ISR) after DES still exists, and its prevalence is not negligible
ecause the population treated with DES is large. Although
he low frequency of ISR events with DES makes clinical
nvestigation difficult, many studies have addressed the inci-
ence, mechanism, predictors, and optimal treatment of DES
estenosis. We sought to provide a concise, comprehensive
verview of the pathophysiologic mechanisms, clinical presen-
ation, morphologic patterns, and management options of
ES ISR.
efinition
estenosis, or reduction in lumen diameter after percutane-
us coronary intervention (PCI), is the result of arterial
amage with subsequent neointimal tissue proliferation.
inary angiographic restenosis is defined as 50% luminal
arrowing at follow-up angiography. Our group first pro-
osed an angiographic classification of restenosis (Table 1)
3). The most widely accepted definition of clinical reste-
osis, assessed as a requirement for ischemia-driven repeat
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ccepted July 27, 2010.evascularization, was proposed by the Academic Research
onsortium. This definition requires both an assessment of
uminal narrowing and the patient’s clinical context
Table 1) (4). In case of an intermediate lesion, the use of
ractional flow reserve or intravascular ultrasound (IVUS)
an guide the clinical decision (5–7).
Although a detailed discussion on stent thrombosis is
eyond the scope of this review, it is important to distin-
uish it from ISR. Stent thrombosis frequently presents as
yocardial infarction (MI), whereas ISR presents as MI in
small minority of cases (8). The Academic Research
onsortium proposed a definition of stent thrombosis that
ound general acceptance (Table 1). The time course for a
LR occurring within 30 days after stent implantation is
oo short to be caused by neointimal hyperplasia but is more
ikely to be caused by a procedural complication or subacute
tent thrombosis. Finally, it is still possible that restenotic
nd thrombotic processes may occasionally coexist. This can
ccur in cases characterized by neointimal hyperplasia plus
ocal thrombosis inside the stent. Many factors can provide
seful tips in a particular case, including the time frame
rom original implantation (the longer the time, the greater
he likelihood of neointimal hyperplasia), angiographic
eatures (size of thrombus, length of stent, and ISR), IVUS
neointimal hyperplasia can be reliably seen and measured),
nd intraprocedural findings (neointimal tissue is hard and
ssociated with balloon slippage, whereas thrombus is soft).
ncidence
he initial pivotal randomized trials comparing DES and
MS were conducted in patients with de novo native
oronary artery lesions, and ISR was observed at follow-up
n 6% of patients (9,10). After these promising initial
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In-Stent Restenosis in the DES Era November 30, 2010:1897–907results, DES were rapidly and
widely adopted, enabling more
complex percutaneous procedures
than in the preceding era. Subse-
quently, restenosis rates increased
to the double-digit domain in ran-
domized head-to-head DES com-
parisons including more complex
patients and lesions (11,12). More-
over, a number of clinical regis-
tries and observational studies that
included complex, unselected pa-
tients reported restenosis rates
higher than 10% (13–15).
The newer DES, such as
everolimus-eluting stents (EES),
zotarolimus-eluting stents (ZES),
and biolimus A9–eluting stents,
are characterized by improve-
ments in stent platform (i.e.,
hin-strut cobalt chromium vs. thick-strut stainless steel),
olymer (thinner and/or biodegradable), and drug (biolimus
efinitions and Classification of Restenosis and Stent ThrombosisTable 1 Definitions and Classification of Restenosis and Stent
Angiographic Reste
Diameter stenosis 50%
Type I focal: 10 mm in length
IA articulation or gap
IB margin
IC focal body
ID multifocal
Type 2 diffuse: 10 mm intrastent
Type 3 proliferative: 10 mm extending beyond the stent margins
Type 4 total occlusion: restenotic lesions with TIMI flow grade of 0
Clinical Restenosis: Assessed Objectively as Req
Diameter stenosis 50% and one of the following:
Positive history of recurrent angina pectoris, presumably related to target vessel
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equiv
Abnormal results of any invasive functional diagnostic test (e.g., coronary flow vel
(and 6.0 mm2 for left main stem) has been found to correlate with abnormal
TLR with diameter stenosis 70% even in absence of the above ischemic signs or s
Stent
Definite stent thrombosis
Angiographic confirmation of stent thrombosis
Presence of thrombus that originates in stent or in the segment 5 mm proxima
Acute onset of ischemic symptoms at rest
New ischemic ECG changes that suggest acute ischemia
Typical rise and fall in cardiac biomarkers
Pathologic confirmation of stent thrombosis
Evidence of recent thrombus within stent determined at autopsy or via examina
Probable stent thrombosis
Any unexplained death within first 30 days
Irrespective of time after index procedure, any MI related to documented acute
Possible stent thrombosis
Any unexplained death from 30 days after intracoronary stenting
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stents(s)
VBT  vascular
brachytherapy
ZES  zotarolimus-eluting
stent(s)ECG electrocardiography; FFR fractional flow reserve; IVUS intravascular ultrasound; MImyocar9 and zotarolimus were specifically designed for use in
ntracoronary stents), with the aim of minimizing the
ncidence of DES ISR and improving safety. Recent large
andomized studies have shown that the next-generation
ES is superior to the first-generation paclitaxel-eluting
tent (PES) in terms of reducing repeat revascularization,
I, and stent thrombosis (16,17).
linical Presentation
lthough some cases of ISR are clinically silent, the
ajority lead to recurrent symptoms. Given its gradual and
rogressive onset, ISR has been perceived as a benign
henomenon. Reports on the presentation of BMS ISR
ave shown that unstable angina is a frequent manifestation
f ISR (26% to 53%). Moreover, depending on the defini-
ions applied, BMS ISR presented as MI in 3.5% to 20% of
atients (18,19). The presentation of DES ISR is similar to
hat of BMS ISR with approximately 16% to 66% of
atients presenting with unstable angina and 1% to 20%
ith MI (18,19). The mechanism of late MI associated with
SR is multifactorial. First, a silent occlusive restenosis can
bosis
and Classification
nt for Ischemia-Driven Repeat Revascularization
presumably related to target vessel
serve, FFR 0.80); IVUS minimum cross-sectional area 4 mm2
nd need for subsequent TLR (5–7)
ms
bosis
tal to stent and at least 1 of the following within a 48-h time window
f tissue retrieved following thrombectomy
ia in territory of stent thrombosis and in absence of any other obvious causeThrom
nosis
uireme
alent),
ocity re
FFR a
ympto
Throm
l or dis
tion o
ischemdial infarction; TIMI Thrombolysis In Myocardial Infarction; TLR target lesion revascularization.
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November 30, 2010:1897–907 In-Stent Restenosis in the DES Erae difficult to differentiate from a thrombotic event. In
ddition, a highly stenotic ISR lesion may also promote
ocal nonocclusive thrombosis and lead to a clinical presen-
ation of non–ST-segment elevation MI or troponin-
ositive unstable coronary syndrome. Based upon the wide
ariety in definitions and reported incidence of unstable
ngina and MI, it is impossible to definitively confirm or
eject that ISR is indeed a benign phenomenon; a spectrum
f the acuity of clinical presentation exists (20–23).
Certain studies have reported biomarker-positive acute
oronary syndrome as presentation of ISR to be a predictor
or further adverse events after treatment of ISR (23,24). In
ontrast, an observational study by Steinberg et al. (25)
howed no differences in the occurrence of subsequent
dverse events after treatment of ISR in patients presenting
ith acute coronary syndrome versus patients presenting
ith recurrent exertional angina.
Of note, in the BMS era, ISR has been reported to occur
n average of 5.5 months after stent implantation, with a
horter interval for patients presenting with MI than those
resenting with recurrent angina (26). Furthermore, diffuse
SR was more frequent in patients with MI and correlated
ith early ISR presentation (26). On the other hand, there
s a paucity of detailed data on the timing of ISR related to
ES. In one study of 39 ISR cases associated with DES,
ee et al. (27) showed that the mean time from PCI to ISR
etection was approximately 12 months. The time frame to
estenosis after DES may indeed be longer than that after
MS because antiproliferative drugs can delay the biologic
esponse to injury.
athophysiologic Mechanisms
he clinical effect of a DES is highly dependent on its
omponents: stent platform, active pharmacologic com-
ound, and drug carrier. DES technology enables anti-
nflammatory, immunomodulatory, and/or antiproliferative
gents to be released in appropriate amounts and distributed
t the site of arterial injury during the initial 30-day healing
eriod. The precise reasons why DES restenose in some
atients and in some segments within the same patient are
ossible Mechanisms of Restenosis After DESTable 2 Possible Mechanisms of Restenosis After DES
Biological factors
Drug resistance
Hypersensitivity
Mechanical factors
Stent underexpansion
Nonuniform stent strut distribution
Stent fracture
Nonuniform drug elution/deposition
Polymer peeling
Technical factors
Barotrauma outside stented segment
Stent gapHtill controversial. Biological, mechanical, and technical
actors may contribute to ISR after DES implantation
Table 2).
iological factors. DRUG RESISTANCE. Sirolimus and its
nalogs have a cytostatic effect. They inhibit the function of
he mammalian target of rapamycin and suppress smooth
uscle cell migration and proliferation by arresting the cell
ycle in the G1 phase (28). Paclitaxel has a cytotoxic effect,
inding specifically to the beta-tubulin subunit of microtu-
ules, and its principle action is to interfere with microtu-
ule dynamics, preventing their depolymerization (28).
ecent data indicate that genetic mutations can influence
he sensitivity to these drugs, conferring resistance to
irolimus, its analogs, or paclitaxel (29,30).
YPERSENSITIVITY. For BMS and first-generation DES,
he predominant stent platform material is 316L stainless
teel. In the BMS era, allergic reactions to nickel and
olybdenum released from 316L stainless steel stents were
otential triggering mechanisms for ISR (31). The platform
aterial used in many novel DES (but not in the widely
sed PES and sirolimus-eluting stent [SES]) is cobalt
hromium, which has a lower nickel content than 316L
tainless steel, and does not appear to trigger the adverse
roliferative response and hypersensitivity that accompanies
he incorporation of other alloys.
However, because DES consist of 3 components (stent
latform, antirestenotic drug, and polymer carrying the
rug), hypersensitivity reactions can be caused by any one of
hese components. In the RADAR (Research on Adverse
rug/Device Events and Reports) project, 5,783 reports of
dverse events after DES placement collected by the Food
nd Drug Administration were analyzed, and 261 reports
escribed hypersensitivity reactions. Subsequently, 17 pa-
ients were identified for which the DES themselves ap-
eared to be a probable cause of hypersensitivity (32). Of the
7 patients with DES hypersensitivity, 4 patients (24%)
ied of stent thrombosis between 4 and 18 months after
tent implantation; this could have been isolated thrombosis
r a combination with progressive/late restenosis. These
eaths led to concern about a possible causative role of
urable polymers that remain on the stent surface after drug
lution. Because the exact incidence is unclear, any patient
uspected of having a hypersensitivity reaction after DES
mplantation should be carefully monitored. New DES with
iodegradable polymers and improved metal alloys would be
xpected to have fewer hypersensitivity problems.
echanical factors. STENT UNDEREXPANSION. Stent un-
erexpansion results from poor expansion during implanta-
ion rather than from chronic stent recoil (Fig. 1) (33). Stent
nderexpansion may be undetectable angiographically in
any cases; suspicion may be raised in an area of fluoro-
copically underexpanded stent struts (compared with the
est of struts) in the context of a calcified lesion or an
nability to fully expand the balloon inside the stent.Residual uncovered atherosclerotic plaques
owever, the use of IVUS can be instrumental to detect
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In-Stent Restenosis in the DES Era November 30, 2010:1897–907nderexpansion; despite good apposition of the stent struts
o the vessel wall, the underexpanded site would be evident
y a stent cross-sectional area significantly smaller than the
essel cross-sectional area in the same site, smaller than the
tent cross-sectional area in other sites, and smaller than
he reference lumen area. According to proposed strict
riteria by de Jaegere et al. (34), excellent expansion is
vident when the minimum lumen area in the stent is90%
f the average reference lumen area.
A condition that needs to be differentiated from under-
xpansion is stent malapposition; unlike underexpansion,
here are stent struts not apposed to the vessel wall (i.e.,
pace occupied by blood can be detected between the stent
truts and the arterial intima). Malapposition cannot be
udged angiographically (except in very few extreme cases),
ypically occurs with use of undersized stents or in arteries
hat have significant tortuosity and fluctuations of reference
rterial lumen diameter within the treated segment, and is
hought to predispose to stent thrombosis (35). However, a
ecent study by Steinberg et al. (36) found no association
etween early or late incomplete stent apposition and stent
hrombosis in 1,580 patients enrolled in IVUS substudies of
arious TAXUS (Treatment of De Novo Coronary Disease
sing a Single Paclitaxel-Eluting Stent) clinical trials.
ecause both malapposition and underexpansion affect se-
ected regions of a stent, it is entirely possible that they
oexist in 2 separate sites of the same stent (e.g., proximal
truts can be malapposed owing to large and tortuous
roximal reference sites, whereas the mid stent area at the
Figure 1 Stent Underexpansion
The white arrow in A shows a mid left anterior descending coronary artery lesion
distal reference lumen diameter, which measured 6.8 mm2. C shows the IVUS im
stent struts, without evidence of neointimal hyperplasia but a small stent cross-se
diameter.riginal lesion site can be underexpanded) (37). IONUNIFORM DRUG DISTRIBUTION. The effectiveness of
ocal drug delivery requires transmural and circumferential
istribution across and within the vessel walls. Physiologic
nd computational models have shown that local blood flow
lterations, strut overlap, and polymer damage may hamper
he uniformity of drug elution (38,39). Treating lesions in
oncompliant vessels increases the odds of stent underex-
ansion, and difficult device delivery may strip the polymeric
aterial with ensuing compromise in local drug elution. In
ddition, variability in vessel wall coverage among the
ifferent types of DES (reflecting the metal-to-artery ratio
f their stent platforms) and variability in drug elution (e.g.,
tripping of coating or nonuniform/circular stent expansion)
ay produce focal areas within the stented segment with
ess than optimal drug distribution and contribute to in-
reased ISR risk (40–42). Achieving drug elution from the
etallic stent and from the stent delivery balloon during
nflation may be a way to address this issue in the future.
TENT FRACTURE. A stent fracture is defined as complete
r partial separation of a stent at follow-up that was
ontiguous after the original stent implantation (43). A
tent fracture eliminates the metal scaffolding support at the
pecific site and adversely impacts local drug delivery. It may
ccur in conjunction with restenosis (typically of a focal
attern), resulting from a decrease in local drug delivery at
he fracture point; it may also be a marker of severe
onuniform stent expansion in a highly mobile and hard
rterial area that ultimately separated the stent (Fig. 2). By
tent implantation. B shows the intravascular ultrasound (IVUS) imaging of the
f the underexpanded stent in the treated lesion, which shows well-apposed
l area (CSA) of only 3.1 mm2; the vessel diameter is almost double the stentafter s
aging o
ctionaVUS, partial stent fracture is defined by the absence of at
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November 30, 2010:1897–907 In-Stent Restenosis in the DES Eraeast one-third or 120° of stent struts for at least 1 frame;
omplete stent fracture is defined by the complete absence
f stent struts within the stented segment for at least 1 frame
43). Furthermore, a number of classification systems for the
everity of stent fracture have been proposed (Table 3)
44–46). The incidence of DES fracture has been reported
o range from 1% to 8% (47–49). The need for subsequent
evascularization in fractured stents has been reported to
ange from 15% to 60% in these relatively small studies
47–49). Right coronary artery lesions, excessive tortuosity,
ngulation and torsion of the vessel, overlapping stents,
onger stents, and SES (owing to its rigid closed-cell
tructure) have been associated with an increased risk of
tent fracture (47–49).
tent Fracture Classification MethodsTable 3 Stent Fracture Classification Methods
Type Popma et al. (45)
1 Single-strut fracture or gap between struts
2 times normal
Single-strut f
2 Multiple strut fractures with V-form
division of stent
Multiple sing
different s
3 Complete transverse stent fracture
without displacement of fractured
fragments 1 mm during cardiac cycle
Multiple sing
complete
without st
4 Complete transverse stent fracture with
abundant movement and displacement
of fractured fragments 1 mm during
cardiac cycle
Complete tra
with stent
Figure 2 Stent Fracture
The gray bars in A are positioned adjacent to a fractured long stent in a right coro
fracture, with clearly visible stent struts across the circumference of the lumen. C
cating a complete fracture. D shows the cross section distal to the stent fracture,echnical factors. BAROTRAUMA OUTSIDE STENTED
EGMENT. Subgroup analyses from an early SES randomized
linical trial indicated that the exposed margins of the stents
hat did not cover the entire region of the balloon injury were
he primary sites of restenosis (10). Restenosis occurred pre-
ominantly at the proximal stent margin after SES placement.
his was decreased in subsequent studies that employed the
urrently recommended technique of pre-dilation with shorter
alloons, use of a single stent long enough to cover the entire
rea of balloon injury, and post-dilation within the stented
egions using short, high-pressure balloons.
TENT GAP. Similar to stent fracture, stent gap causes discon-
inuous coverage with DES. A short gap between 2 DES
t al. (44) Scheinert et al. (46)
only Minor: single-strut fracture
t fractures occurring at Moderate: fracture 1 strut
t fractures resulting in
erse linear fracture but
placement
Severe: complete separation of stent segments
e linear type 3 fracture
cement
rtery. B shows the intravascular ultrasound cross section proximal to the stent
the cross section at the site of stent fracture with no visible stent struts, indi-
stent struts are again visible across the circumference of the lumen.Allie e
racture
le-sten
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le-sten
transv
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In-Stent Restenosis in the DES Era November 30, 2010:1897–907ypically occurs in a zone of balloon injury owing to either pre-
r post-dilation. Local drug deposition in the vessel wall is
inimal at the gap site. In general, considering the reported
afety and efficacy of overlapping DES, and the mechanism
escribed previously, short stent gaps should be avoided (50).
ESIDUAL UNCOVERED ATHEROSCLEROTIC PLAQUES. The
TLLR (Stent Deployment Techniques on Clinical Out-
omes of Patients Treated With the Cypher Stent) trial
valuated the frequency of suboptimal PCI and its impact
n the long-term outcomes of 1,557 patients treated with
ES (51). The presence of geographic miss during the
rocedure (injured or diseased segment not covered by DES
r balloon-artery size ratio 0.9 or 1.3) was associated
ith an increased risk of target vessel revascularization and
I at 1 year. Therefore, the risk and cost of implanting
dditional DES in such cases should be weighed against the
isk of subsequent clinical events.
redictors
redictive factors for DES restenosis, such as diabetes mellitus,
omplex lesions (B2/C), small vessels, longer stents, and stent
nderexpansion, identified from real-world data seem to be
imilar to those for BMS restenosis (Table 4) (13,52,53).
ecause the post-procedural minimal lumen diameter is a
ajor factor in restenosis, obtaining optimal acute angio-
raphic results after DES implantation remains important.
elayed Restenosis
fter DES implantation, late restenosis and persistent
eointimal growth have been reported. In the TAXUS II
tudy, serial IVUS analyses were performed in 161 patients
p to 2 years after deployment of BMS and PES (54).
hereas a modest late decrease in neointimal hyperplasia
as observed in the BMS group, a small late increase in
eointimal tissue was observed in the PES group. However,
ven at 2 years, the neointimal area remained significantly
maller in the PES arm compared with the BMS arm. This
ate “catch-up” phenomenon has also been observed in other
ES types. Aoki et al. (55) reported serial IVUS neointimal
redictors of ISR or TLR After DES ImplantationTable 4 Predictors of ISR or TLR After DES Implantation
Patient
Characteristics
Lesion
Characteristics
Procedural
Characteristics
Age
Female sex
Diabetes mellitus
Multivessel coronary
artery disease
ISR
Bypass graft
Chronic total occlusion
Small vessels
Calcified lesion
Ostial lesion
Left anterior descending
coronary artery lesion
Treatment of multiple
lesions
Type of DES
Final diameter stenosis
ES  drug-eluting stent(s); ISR  in-stent restenosis; TLR  target lesion revascularization.olume measurements at 2 and 4 years in 23 patients ieceiving SES. A modest, nonsignificant increase in neoin-
imal volume occurred between 2 and 4 years. Furthermore,
he 2-year angiographic and IVUS results of the SPIRIT II
Clinical Evaluation of the Xience V Everolimus Eluting
oronary Stent System in the Treatment of Patients With
e Novo Native Coronary Artery Lesions) trial suggested a
imited late neointimal “catch up” in the EES group (56).
his increase in neointimal hyperplasia did not translate
nto higher TLR in the EES group. A recent study
omparing SES, ZES, and a polymer-free dual DES (elut-
ng probucol and sirolimus) showed similar efficacy in terms
f angiographic binary restenosis at 6 to 8 months between
he SES (12.0%) and dual DES (11.0%), both of which
erformed significantly better than the ZES (19.3%, p 
.003). A modest late “catch up” in terms of restenosis and
LR was observed with the first-generation SES but not
ith the dual DES or the ZES (which still had higher
umulative late lumen loss) (57).
The precise reason for the late increase in neointimal
yperplasia in DES is still unclear, but it may be related to
delayed healing response, persistent biological reaction
aused by the drug soon after implantation, or a hypersen-
itivity reaction to durable polymer. Further study is war-
anted to investigate the clinical relevance of this persistent
eointimal growth and establish the appropriate length of
ollow-up after DES implantation.
orphologic Patterns
oth the incidence and angiographic patterns of restenosis
iffer between DES and BMS ISR. Table 5 shows mor-
hologic patterns of ISR in SES, PES, and BMS. The
redominant restenosis patterns in BMS are nonfocal types.
ngiographic restenosis patterns following different types of
ES may not be identical. The most frequent restenosis
attern after SES is focal, and the majority of ISR after PES
s also focal (9,21,23,58–63). Interestingly, DES ISR pat-
erns in the randomized SIRIUS (Sirolimus-Eluting Stent
n Coronary Lesions) and TAXUS IV trials are relatively
ore often focal compared with DES ISR patterns in
bservational studies. These differences might be explained
y the fact that patients included in the randomized trials
ad relatively less complex lesions.
rognostic implications of morphologic patterns of ISR.
fter BMS implantation, the classification of angiographic
atterns of ISR has important prognostic significance (3).
fter DES implantation, the morphologic pattern of DES
SR remains an important predictor of clinical outcomes
fter ISR treatment (23,64). Cosgrave et al. (64) reported
he rate of ISR recurrence following previous successful
ES ISR treatment to be 18% in the focal group and 51%
n the nonfocal group; the incidence of TLR at a median of
4 months was 10% and 23%, respectively. Rathore et al.
23) reported that a focal pattern of SES ISR was an
ndependent predictor of lower recurrent restenosis rate,
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November 30, 2010:1897–907 In-Stent Restenosis in the DES Eraith a hazard ratio of 0.47 in a cohort of 351 patients
reated for SES ISR.
linical Approach and Treatment Options
he optimal treatment for DES restenosis remains unde-
ned. The variety of treatment options (conventional bal-
oon angioplasty, cutting or scoring balloon, drug-eluting
alloon, BMS, same DES, different DES, vascular brachy-
herapy [VBT], or bypass surgery) and the variable etiolo-
ies of DES restenosis make it difficult for interventional
ardiologists to determine the optimal therapy for this
ondition, except for the almost uniform avoidance of VBT.
o far only 1 randomized clinical trial investigating the
reatment of DES ISR has been published. Many observa-
ional studies have evaluated clinical and angiographic
utcomes after percutaneous treatment for DES restenosis.
orphologic Pattern of SES, PES, and BMS ISRTable 5 Morphologic Pattern of SES, PES, and BMS ISR
Study/First Author
(Ref. #) Year
SES
n Focal Nonfocal
Randomized trials
SIRIUS 2004 31 83.9% 16.1%
TAXUS IV 2004 — — —
Observational studies
Lemos et al. (59) 2003 20 75.0% 25.0%
Colombo et al. (62) 2003 14 100.0% 0.0%
Iakovou et al. (60) 2005 — — —
Corbett et al. (61) 2006 150 71.3% 28.7%
Park et al. (21) 2007 97 76.3% 23.7%
Kitahara et al. (63) 2009 124 79.0% 21.0%
Rathore et al. (23) 2010 487 47.0% 53.0%
MS  bare-metal stent(s); ISR  in-stent restenosis; PES  paclitaxel-eluting stent(s); SES  sir
linical and Angiographic Outcomes After Percutaneous TreatmentTable 6 Clinical and Angiographic Outcomes After Percutaneou
Study/First Author
(Ref. #) Year
No. of
Lesions Type of DES
Randomized trial
ISAR-DESIRE 2 2010 450 SES 6–
Observational studies
Lemos et al. (68) 2004 24 SES 9.
Moussa et al. (70) 2006 22 SES 12
Lee et al. (67) 2006 140 SES 7.
Torguson et al. (71) 2006 111 PES 22%, SES 78% 8
Kim et al. (66) 2006 58 PES 47%, SES 53% 12
Cosgrave et al. (64) 2006 250 PES 34%, SES 66% 9
Mishkel et al. (69) 2007 108 SES, PES 15
Garg et al. (65) 2007 116 SES, PES 12
Solinas et al. (20) 2008 152 PES 22%, SES 78% 12
Bonello et al. (72) 2008 122 N/A 12
Chatani et al. (73) 2009 140 SES 2
Steinberg et al. (22) 2009 119 N/A 12
Rathore et al. (23) 2010 351 SES 9
Tagliareni et al. (75) 2010 252 PES 39%, SES 57%, ZES 4% 23
Singh et al. (74) 2010 319 N/A 3.These rates are for target vessel revascularization.
BA  balloon angioplasty; DES  drug-eluting stent(s); TLR  target lesion revascularization; VBT  vaowever, the numbers of enrolled patients in these studies
ave been too small, the treatment modalities too diverse,
nd the results too inconsistent to draw any definitive
onclusions about the optimal treatment of DES ISR
Table 6) (20,22,23,64–75).
An intravascular imaging technique (ultrasound being the
ost common) may reveal the mechanism of DES ISR in a
pecific case and guide further therapy. From a technical
oint of view, a larger high-pressure balloon may be useful
n ISR cases owing to original stent underexpansion. A
ommon technical problem of balloon angioplasty in ISR is
he slippage during inflation, which can be avoided with use
f a cutting or scoring balloon; however, the cutting or
coring balloon may in turn be somewhat more difficult to
eliver in distal areas through stented segments. Drug-
luting balloons provide the theoretic advantage of avoiding
PES BMS
n Focal Nonfocal n Focal Nonfocal
— — — 128 43.0% 57.0%
16 62.5% 37.5% 65 30.8% 69.2%
— — — — — —
— — — — — —
98 50.0% 50.0% — — —
149 51.7% 48.3% — — —
80 51.3% 48.7% — — —
— — — — — —
— — — 351 19.3% 90.7%
eluting stent(s).
ES ISRatment of DES ISR
w-up
ation TLR
Angiographic
Restenosis Treatment Modalities Used
ths 16.7% 18.0% PES 50%, SES 50%
ths 20.8% 42.9% BA 11%, BMS 4%, PES 41%, SES 44%
hs 23.0% N/A BA 13.5%, BMS 82%, VBT 4.5%
8 months 14.0% N/A PES 100%
s 13.5% N/A PES 11%, SES 34%, VBT 55%
hs 5.2% 16.7% BA 19%, SES 57%, VBT 24%
s 14.4% 28.4% BA 38%, DES 62%
onths 28.2% N/A BA 1%, BMS 18%, DES 80%, VBT 1%
hs 15.7% N/A SES, PES
hs 8.3% N/A BA 16%, DES 84%
hs 10.0% N/A VBT
33.7% 32.5% OTHER 35%, PES 22%, SES 43%
hs 22.2%* N/A DES
s 37.0%* 41.1% BA 67%, BMS 1%, PES 5%, SES 17%
months 11.8% N/A BA 53%, DES 47%
15.0% N/A N/Aof Ds Tre
Follo
Dur
8 mon
3 mon
mont
2 1.
month
mont
month
 6 m
mont
mont
mont
yrs
mont
month
 10
2 yrsscular brachytherapy; ZES  zotarolimus-eluting stent(s); other abbreviations as in Table 5.
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In-Stent Restenosis in the DES Era November 30, 2010:1897–907ew stent implantation in cases of excess neointimal prolif-
ration as the dominant cause of ISR.
ES or cutting/scoring balloon angioplasty for DES
estenosis. Clinical and angiographic results with DES for
MS restenosis were superior to those from conventional
herapy (balloon angioplasty or VBT) in several randomized
rials (76–78). DES are also currently the most popular
etreatment modality for DES restenosis, particularly of the
ocal type, because of immediate feasibility and safety.
everal observational studies compared the clinical or an-
iographic effect of repeat-DES placement with that of
ther therapies (66,69,71). Kim et al. (66) (n 58) reported
ignificantly lower 6-month restenosis rates after new SES
reatment (4%) compared with 35% with conventional
reatment (cutting balloon angioplasty or VBT). Mishkel et
l. (69) reported similar results in 108 DES failure lesions.
he 1-year TLR rate was 29% in patients given the same
ES, 19% with a different DES, and 37% with conven-
ional (cutting balloon angioplasty, BMS, or VBT) treat-
ents. A recent observational study (n  211) reported no
ifferences in TLR rates at a mean follow-up period of 2
ears between repeat DES and balloon angioplasty (75).
owever, patients in the repeat DES group more often had
diffuse pattern of restenosis at baseline. A well-targeted,
mall, randomized study was recently conducted on 197
ES patients with ISR (79). The investigators assigned the
atients (original DES were 55% SES and 45% PES) to
reatment with either SES or balloon angioplasty alone, and
eported a trend toward lower target lesion revascularization
ith SES (5.9% vs. 13.1%, p  0.097); switching the type
f DES implanted (relative to the original one) did not
ppear to confer any significant benefit or risk. However,
hese initial results are subject to the limitations of the
redominantly focal type ISR and the small sample size of
his study. Notably, no randomized studies to date have
ompared DES retreatment with bypass surgery or cutting/
coring balloon angioplasty.
ame DES or different DES. One of the etiologies of
ES restenosis is drug resistance. Therefore, the placement
f a DES eluting a different drug might more effectively
reat DES restenosis than an identical DES. Few studies
ave investigated same or different DES implantation for
ES restenosis; in general, these studies have compared
ES versus PES. To date, there have been no reports on the
se of ZES, EES, or biolimus A9–eluting stents. The
SAR-DESIRE (Intracoronary Stenting and Angiographic
esults: Drug Eluting Stents for In-Stent Restenosis) trial
andomized 450 patients with SES restenosis to treatment
ith a same DES (homo-DES) or a different DES (hetero-
ES [i.e., PES]) (80). The mean lesion lengths were 12.7
nd 12.5 mm, respectively, and the majority of patients had
focal pattern of restenosis (65% and 61%, respectively). No
ignificant differences were observed in terms of in-stent late
umen loss at 6 to 8 months’ follow-up (0.40 0.65 mm vs.
.38  0.59 mm) or in 1-year clinical end points of TLR W17% vs. 15%), death/MI (6.1% vs. 5.8%), and stent
hrombosis (0.4% in both groups).
These results may reflect that focal ISR might not be due
o drug resistance but rather to a gap, injury zone mismatch,
racture, localized imperfect drug elution, polymer disrup-
ion during device delivery, or their combinations. Diffuse
SR has a greater chance to be due to drug resistance, and
erhaps future studies with alternate DES treatment should
ocus solely on the diffuse ISR pattern.
BT. A small number of observational studies have inves-
igated the use of VBT as a treatment option for DES ISR
71,72). Torguson et al. (71) reported a significantly lower
ate of a composite end point of death, MI, or target vessel
evascularization at 8 months in patients treated with VBT
elative to patients treated with DES for DES ISR. How-
ver, the investigators did not use a multivariate model to
djust for possible confounders in this retrospective study.
oreover, because of high rates of late restenosis and logistic
ssues, the use of VBT has declined in recent years, and most
ospitals no longer possess the necessary set-up (81).
oronary artery bypass graft surgery. The variability of
he results of interventional treatment of DES ISR neces-
itates the consideration of coronary artery bypass graft
urgery as a treatment option in complex cases (e.g.,
ultivessel DES with multivessel ISR, especially diffuse or
ven single-vessel ISR at a very critical lesion location).
Although not specifically outlined in any guideline doc-
ment, a patient treated with a new DES for ISR should be
onsidered high risk and should continue on dual antiplate-
et therapy unless a complication emerges. Therefore, the
rack record of dual antiplatelet adherence until ISR devel-
pment is also important because any complication or
oncompliance issues may preclude further interventional
reatment options and favor coronary artery bypass graft
election.
uture Directions
everal randomized trials investigating treatment strategies
or DES ISR are currently ongoing. The randomized
ISE-CROSS (DES Crossover for In-Stent Restenosis)
rial is evaluating same versus different DES as alternate
herapies for DES restenosis. Moreover, 2 Korean multi-
enter trials are currently enrolling patients. The DES-ISR
rial is evaluating the relative efficacy of PES and SES for
iffuse DES ISR, and the FOCUS (Focal In-Stent Reste-
osis After Drug-Eluting Stent) trial compares cutting
alloon angioplasty with SES for focal DES ISR.
The drug-eluting balloon is another novel promising
odality to treat DES ISR. The theoretic advantage of a
rug-eluting balloon over DES could be that it allows for
elivery of an antirestenotic agent without adding a second
ayer of metal. The drug-eluting balloon has been shown to
e effective in the treatment of BMS ISR (82,83). The
EPCAD-DES (Treatment of DES In-Stent Restenosis
ith SeQuent Please Paclitaxel Eluting PTCA Catheter)
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November 30, 2010:1897–907 In-Stent Restenosis in the DES Erarial is currently recruiting patients to investigate the efficacy
f a paclitaxel-eluting balloon for the treatment of DES
SR.
roposed Clinical Approach Algorithm
t is important to consider that therapeutic options for DES
estenosis are somewhat controversial because there are few
ata comparing interventional modalities (balloon, cutting
alloon, scoring balloon, drug-eluting balloon, BMS, same
ES, different DES, or VBT) with surgery. Therefore, we
ecommend that treatment of DES restenosis be “individ-
alized” using IVUS analysis to clarify the etiologic mech-
nism. Figure 3 depicts a proposed algorithm for the current
pproach to DES restenosis.
onclusions
ES result in reduced rates of restenosis compared with BMS
cross all lesion and patient subsets. Angiographic coronary
estenosis rates after DES implantation have fallen below 10%
n several randomized trials. However, this rate increases when
omplex lesions are treated. Although predictors of restenosis
fter BMS deployment—such as diabetes mellitus, small ves-
els, and stenting long lesions—are still significant in the era of
ES, the morphologic pattern of restenosis is different follow-
ng BMS versus DES implantation. The predominant pattern
f angiographic restenosis is focal, and this pattern is related to
etter prognosis. However, a diffuse pattern type still exists and
s associated with a high incidence of restenosis recurrence. In
ddition, the issues of delayed restenosis and the mechanisms
f restenosis with DES have not been fully investigated with
DE
Focal (<10mm)
Body of stent, or Gap Ed
Stent underexpansion
Balloon 
Stent fracture
Short DES
Others
Short DES (possibly of different type)
Balloon (consider cutting, scoring or          
ddrug-eluting balloon)
Short D
Figure 3 Algorithm for the Treatment of DES Restenosis
DES  drug-eluting stent(s); IVUS  intravascular ultrasound.hese devices. Further detailed studies are warranted to under-tand the development of restenosis in DES and its precise
reatment. We anticipate that these studies will become more
omplex with the emergence of new types of DES.
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